Core Viewpoint - Lijun Pharmaceutical (01513) reported a mixed performance for the first half of 2025, with a slight decline in revenue but an increase in net profit, reflecting effective R&D management and the application of AI digital tools [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 6.272 billion yuan, a year-on-year decrease of 0.17% [1] - The net profit attributable to shareholders was around 1.281 billion yuan, representing a year-on-year increase of 9.4% [1] - Basic earnings per share stood at 1.43 yuan [1] R&D Pipeline - As of July 31, 2025, the company had a total of 39 products in the research and development pipeline [1] - Among these, 13 products are in the registration phase, 4 in Phase III clinical trials, 2 in process validation/bioequivalence stage, and 4 in Phase II clinical trials [1] - The company emphasized the successful implementation of R&D results, supported by optimized management and deep application of AI digital tools [1]
丽珠医药涨超6% 上半年纯利同比增长9.4%至约12.81亿元